According to Zhitong Finance App, Gelin Biotech (301688.SZ) released its report for the third quarter of 2026. The company achieved operating income of 876 million yuan in the first three quarters, up 6.69% year on year; net profit attributable to shareholders of listed companies was 139 million yuan, down 3.20% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 137 million yuan, down 3.58% year on year; basic earnings per share were 1.34 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.